Quantbot Technologies LP Chemo Centryx, Inc. Transaction History

Quantbot Technologies LP

$2.36 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 09, 2022	SELL	$15.36 - $27.51 $119,331 - $213,725	-7,769 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $32,818 - $57,780	-1,477 Reduced 15.97%	7,769 $194,000
Q4 2021 Feb 11, 2022	BUY	$18.38 - $40.5 $169,941 - $374,463	9,246 New	9,246 $336,000
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $24,765 - $34,200	-500 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $23,625 - $32,580	500 New	500 $30,000
Q1 2020 May 13, 2020	SELL	$32.73 - $50.78 $81,824 - $126,950	-2,500 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$6.81 - $39.55 $17,025 - $98,875	2,500 New	2,500 $98,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.